OLD National Bancorp IN Purchases 38,631 Shares of Novo Nordisk A/S $NVO

OLD National Bancorp IN boosted its position in Novo Nordisk A/S (NYSE:NVO) by 317.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 50,785 shares of the company’s stock after acquiring an additional 38,631 shares during the period. OLD National Bancorp IN’s holdings in Novo Nordisk A/S were worth $2,584,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVO. Franklin Resources Inc. raised its stake in Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors raised its stake in Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after acquiring an additional 6,092,192 shares during the period. Boston Partners bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $310,199,000. SG Americas Securities LLC raised its stake in Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock valued at $132,242,000 after acquiring an additional 2,274,925 shares during the period. Finally, Clear Street Group Inc. bought a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $56,378,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Down 1.6%

NVO stock opened at $38.54 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $172.07 billion, a PE ratio of 11.11, a PEG ratio of 9.32 and a beta of 0.73. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The stock has a 50-day simple moving average of $39.30 and a two-hundred day simple moving average of $47.94.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, equities analysts predict that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were issued a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 50.43%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NVO shares. Wolfe Research started coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating on the stock. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. CICC Research assumed coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price for the company. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $65.56.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Late‑stage trial: oral semaglutide met its main goal in a trial of 10–17 year olds with type 2 diabetes, supporting a planned U.S. approval push and expanding the drug’s potential label into pediatrics — a clear pipeline positive. Novo Nordisk’s new weight-loss pill meets main goal in late-stage diabetes study
• Positive Sentiment: Regulatory/launch implication: company and press reports say Novo plans to seek approval for the oral semaglutide pill to treat younger patients — success here could broaden long‑term revenue and strengthen the oral GLP‑1 franchise. Novo Nordisk to Seek Approval for Pill to Treat Diabetes in Young Patients
• Neutral Sentiment: Market reaction note: coverage highlights that NVO has dipped more than broader markets today, reflecting investor caution despite the clinical win. Novo Nordisk (NVO) Sees a More Significant Dip Than Broader Market
• Neutral Sentiment: Industry context: broader longevity/GLP‑1 debate and sector capital flows are keeping large cap GLP‑1 names (including Novo) in focus but add volatility rather than immediate directional news. The Longevity Trade Is No Longer a Buzzword — It’s a $120 Billion Market
• Negative Sentiment: Analyst downgrade/target cut: Citigroup trimmed its price target for Novo (maintaining a Neutral rating), signaling lower near‑term expectations and contributing to selling pressure. NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact
• Negative Sentiment: Competitive/strategy concerns: commentary questions whether the GLP‑1 “golden age” can continue for incumbents and flags intensifying competition — a negative for long‑term growth multiple assumptions. Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It?
• Negative Sentiment: Distribution/competitive move: Eli Lilly’s expanding direct‑to‑consumer channels (e.g., LillyDirect partnerships) may intensify commercial competition for GLP‑1 products and distribution, a potential headwind for market share. Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.